Comparative Pharmacology
Head-to-head clinical analysis: CENOBAMATE versus PARADIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENOBAMATE versus PARADIONE.
CENOBAMATE vs PARADIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
100 mg orally three times daily; maximum 600 mg/day.
None Documented
None Documented
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
12-24 hours (terminal); prolonged in renal impairment
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Category C
Category C
Anticonvulsant
Anticonvulsant